Aktiesnakken — Maj 2011
-
ja de 80 mill dækker, som jeg forstod på CC sidst også de udgifter der måtte være i 2012
-
ja. overgangen til named patients projekterne tages ikke iår
-
men burde så være fuldt afdækket i år
-
Nu er vi på O studie 58! http://clinicaltrials.gov/ct2/show/NCT01361711?term=ofatumumab&rank=31
-
Zalu er så godt som lukket med undtagelse af Dahanca http://clinicaltrials.gov/ct2/results?term=zalutumumab
-
149 mw til vestas i canada
-
"desværre" efterårs-2012 ordre
-
-
VWS incl.
tiårig servicekontrakt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind